Safety, Tolerability, and Pharmacokinetics of Anti-SARS-CoV-2 Immunoglobulin Intravenous (Human) Investigational Product (COVID-HIGIV) in Healthy Adults: a Randomized, Controlled, Double-Blinded, Phase 1 Study-Reference-Cited by-同舟云学术

Safety, Tolerability, and Pharmacokinetics of Anti-SARS-CoV-2 Immunoglobulin Intravenous (Human) Investigational Product (COVID-HIGIV) in Healthy Adults: a Randomized, Controlled, Double-Blinded, Phase 1 Study

Published:2023-02-28 Issue: Volume: Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Liu Sean T. H.¹^ORCID,Mirceta Mila²,Lin Grace²,Anderson Deborah M.²,Broomes Tarashon¹,Jen Alina¹,Abid Ashley¹,Reich David¹,Hall Christine²,Aberg Judith A.¹^ORCID

Affiliation:

1. Division of Infectious Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA

2. Emergent BioSolutions Canada, Inc., Winnipeg, Manitoba, Canada

Abstract

Anti-SARS-CoV-2 immunoglobulin (human) investigational product (COVID-HIGIV) is a purified immunoglobulin preparation containing SARS-CoV-2 polyclonal antibodies. This single-center clinical trial aimed to characterize the safety and pharmacokinetics of COVID-HIGIV in healthy, adult volunteers.

Funder

U.S. Department of Defense

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/aac.01514-22

Reference30 articles.

1. Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization

2. Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies

3. In vivo monoclonal antibody efficacy against SARS-CoV-2 variant strains

4. FDA. 2021. Fact sheet for healthcare providers EUA of sotrovimab. https://www.fda.gov/media/149534/download. Accessed 15 March 2022.

5. FDA. 2021. Fact sheet for healthcare providers EUA of bamlanivimab and etesevimab. https://www.fda.gov/media/145802/download. Accessed 15 March 2022.

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Passive antibody therapy in emerging infectious diseases;Frontiers of Medicine;2023-12-02